TARC His
- Known as:
- TARC histidine
- Catalog number:
- CHM-359
- Product Quantity:
- 2µg
- Category:
- -
- Supplier:
- Prospecbio
- Gene target:
- TARC His
Related genes to: TARC His
- Gene:
- CCL17 NIH gene
- Name:
- C-C motif chemokine ligand 17
- Previous symbol:
- SCYA17
- Synonyms:
- TARC, ABCD-2
- Chromosome:
- 16q21
- Locus Type:
- gene with protein product
- Date approved:
- 1996-10-26
- Date modifiied:
- 2016-10-05
Related products to: TARC His
(Des-Gly10,D-His(Bzl)6,Pro-NHEt9)-LHRH (Histrelin) - EIA Kit,(Des-Gly10,D-His(Bzl)6,Pro-NHEt9)-LHRH (Histrelin) - EIA Kit, Host Rabbit, High Sensitivity, CE-marked(Des-Gly10,D-His(Bzl)6,Pro-NHEt9)-LHRH (Histrelin) - EIA Kit, Host RabbitHigh SensitivityCE-marked(Des-Gly10,D-His(Bzl)6,Pro-NHEt9)-LHRH (Histrelin) - EIA Kit, Host: Rabbit, High Sensitivity, CE-marked(Des-Gly10,D-His(Bzl)6,Pro-NHEt9)-LHRH (Histrelin) - EIA Kit, Host: Rabbit, High Sensitivity, CE-marked(Des-Gly10,D-His(Bzl)6,Pro-NHEt9)-LHRH (Histrelin) - Purified Antiserum - IgG(Des-Gly10,D-His(Bzl)6,Pro-NHEt9)-LHRH (Histrelin) - Purified Antiserum - IgG, Host Rabbit(Des-Gly10,D-His(Bzl)6,Pro-NHEt9)-LHRH (Histrelin) - Purified Antiserum - IgG, Host Rabbit(Des-Gly10,D-His(Bzl)6,Pro-NHEt9)-LHRH (Histrelin) - Purified Antiserum - IgG, Host: Rabbit(Des-Gly10,D-His(Bzl)6,Pro-NHEt9)-LHRH (Histrelin) - Purified Antiserum - IgG, Host: Rabbit(Des-Gly10,D-His(Bzl)6,Pro-NHEt9)-LHRH (Histrelin), High Sensitivity ELISA(Des_Gly10,His(Bzl)6,Pro_NHEt9)_LHRH Salt _ Binding _ Synonym (His(Bzl)6)_Histrelin SumFormula C66H86N18O12(Des_Gly10,His(Bzl)6,Pro_NHEt9)_LHRH Salt _ Binding _ Synonym (His(Bzl)6)_Histrelin SumFormula C66H86N18O12(His(1_Me)2)_LHRH Salt Trifluoroacetate Binding _ Synonym (His(t_Me)2)_LHRH SumFormula C56H77N17O13(His(1_Me)2)_LHRH Salt Trifluoroacetate Binding _ Synonym (His(t_Me)2)_LHRH SumFormula C56H77N17O13 Related articles to: TARC His
- : The itch-scratch cycle is a key driver of exacerbation in atopic dermatitis (AD) and requires objective monitoring, yet patient-reported itch scores are often unreliable in children. This study aimed to evaluate smartwatch-derived nocturnal scratching metrics as digital biomarkers of disease activity and treatment response in pediatric AD. : In this prospective observational study, 50 children (median age 9 years) with physician-diagnosed AD wore an Apple Watch with the Itch Tracker application for 5-14 nights during initiation of topical therapy. Three scratch metrics-scratch count rate (SCR), scratch duration ratio (SDR), and scratch burden index (SBI, duration × intensity)-were analyzed. Associations with clinical outcomes [Eczema Area and Severity Index (EASI), Patient-Oriented Eczema Measure (POEM)], serum thymus and activation-regulated chemokine (TARC), and itch numerical rating scale (NRS) were examined. Logistic regression models were evaluated to examine whether these metrics could identify children who achieved clinically meaningful improvement, defined as EASI-50 plus ≥ 4-point POEM reduction. : All scratch metrics correlated with baseline EASI (r = 0.60-0.64, < 0.001) and serum TARC (r = 0.58-0.60, < 0.001). Reductions in scratching paralleled clinical improvement (r = 0.67-0.71, < 0.0001). Among models, the SBI-based logistic regression demonstrated the best discriminative performance (AUC = 0.78, 95% CI: 0.64-0.92). : Wearable-derived nocturnal scratching metrics showed moderate but consistent associations with disease severity and short-term improvement. Although predictive capability remains to be established, these metrics may serve as treatment-responsive digital measures. Given the cross-sectional nature of biomarker analyses and other study limitations, further prospective validation is required before clinical application in real-world pediatric AD monitoring. - Source: PubMed
Publication date: 2026/04/28
Iwai FumikoNishida TakahiroKanai ReiArima TomoyukiTakase TakafumiYamada ShingoNagao MizuhoSuga ShigeruKubota HitokiOkamoto KazuakiIkoma AkihikoFujisawa Takao - Pruritus is a common and distressing symptom among dialysis patients, yet its underlying mechanisms remain incompletely understood. Most previous research has focused on systemic inflammatory markers, while little is known about local skin alterations contributing to pruritus. This study aimed to characterize skin biomarker profiles in dialysis patients with pruritus, in comparison with dialysis patients without pruritus and healthy controls, and to explore differences between pruritic and non-pruritic skin sites. - Source: PubMed
Publication date: 2026/05/09
van Lieshout Thomas SBennett ShannahVreeken JopKezic SanjaKemperman Patrick M J HLuiten Rosalie MSpithoven Edwin MPenne Erik LRustemeyer Thomasvan Jaarsveld Brigit CAbrahams Alferso C - Knee osteoarthritis (KOA) is a degenerative bone and joint disease. Jingu Zhitong Gel (JGZTG) exhibits a promising therapeutic effect in the clinical treatment of knee osteoarthritis (KOA). However, the mechanism of JGZTG in treating KOA remains unclear. - Source: PubMed
Publication date: 2026/04/17
Li LuLiang YiyaoDong JingSu ZhenzhenXu XinyuWu ZiyinZhang XinzhuangLi JifengWang ZhenzhongLiu WenjunCao LiangXiao Wei - Myocardial fibrosis is a key pathological process driving the progression of cardiovascular diseases toward heart failure, closely linked to persistent inflammation and immune dysregulation. Among CC chemokines, CCL17 has emerged as an important mediator connecting immune cell dynamics with fibrotic remodeling. This review outlines current understanding of the cellular sources, regulatory mechanisms, and functional roles of CCL17, with particular attention to its impact on regulatory T cell (Treg) recruitment through ligand-biased signaling. Beyond this mechanism, CCL17 likely operates within a broader inflammatory network, with potential interactions involving CCR2 macrophages and IL-17-related pathways. Experimental studies show that disruption of CCL17 signaling attenuates fibrosis and improves cardiac function, while clinical data link elevated circulating CCL17 to cardiac dysfunction and adverse outcomes. However, the absence of clinical trials and the redundancy of chemokine networks remain key challenges for translation. Overall, CCL17 may serve as a biomarker and therapeutic target, although its clinical application will require a more integrated, network-based understanding. - Source: PubMed
Publication date: 2026/04/12
Cai WeitingZhao JingZhang Zheng - Cutaneous gene therapy has the potential to treat a wide range of skin disorders, but effective delivery remains limited by the skin's barrier properties and immune surveillance. Here, we identify AAVrh32.33 as a potent vector for targeting dermal stromal compartments. Following systemic administration in mice, AAVrh32.33 mediated robust and durable transgene expression, with preferential targeting of dermal fibroblasts and hair follicle bulge cells. Expression peaked at one month and persisted for up to two years, highlighting its suitability for chronic conditions. To reduce immunogenicity, a dominant CD8 T cell epitope was disrupted, generating the IDPΔ variant. This modification attenuated peptide-specific T cell responses while preserving stromal transduction. In human skin explants, IDPΔ achieved high levels of gene expression, primarily in dermal fibroblasts and precursors, confirming translational relevance. Finally, vectors encoding CCL17, CCL20, and CCL22 demonstrated localized targeted therapeutic gene delivery in both healthy and inflamed skin, underscoring the feasibility of using this platform to reshape local immune responses. Together, these findings establish AAVrh32.33 and IDPΔ as promising platforms for durable cutaneous gene therapy, with direct applications in diseases such as vitiligo where long-term modulation of the dermal microenvironment is essential. - Source: PubMed
Publication date: 2026/05/01
Arjomandnejad MotaharehEssien KingsleySylvia KatelynBlackwood MeghanTutto AmandaKatz EricaTang QiushiHarris John EKeeler Allison M